横浜市立大学 内分泌・糖尿病内科

主要論文

2020年

  1. Shirakawa J, Terauchi Y. Potential linkage between DPP-4 inhibitor use and the risk of pancreatitis/pancreatic cancer. J Diabetes Investig. 2019 Nov 27. doi: 10.1111/jdi.13192. [Epub ahead of print] PubMed PMID: 31774618.
  2. Shirakawa J, Terauchi Y. Newer perspective on the coupling between glucose-mediated signaling and β-cell functionality. Endocr J. 2019 Nov 6. doi: 10.1507/endocrj.EJ19-0335. [Epub ahead of print] PubMed PMID: 31694991.
  3. Shirakawa J, Tajima K, Okuyama T, Kyohara M, Togashi Y, De Jesus DF, Basile G, Kin T, Shapiro AMJ, Kulkarni RN, Terauchi Y. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. Diabetologia. 2020 Mar;63(3):577-587.
  4. Miya A, Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study Health Study. J Diabetes Investig. 2020 Jan 30;11(4):964-70.
  5. Matsuba I, Kanamori A, Takihata M, Takai M, Maeda H, Kubota A, Iemitsu K, Umezawa S, Obana M, Kaneshiro M, Kawata T, Takuma T, Takeda H, Machimura H, Mokubo A, Motomiya T, Asakura T, Kikuchi T, Matsuzawa Y, Ito S, Miyakawa M, Terauchi Y, Tanaka Y. Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study. Diabetes Technol Ther. 2020 Mar;22(3):228-234. doi: 10.1089/dia.2019.0372. Epub 2020
  6. Iijima T, Aoki K, Kondo Y, Terauchi Y. Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial. J Clin Med Res. 2020 Feb;12(2):73-78. doi: 10.14740/jocmr4084. Epub 2020 Feb 1.
  7. Orime K, Terauchi Y. Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2020 Sep 29:
  8. Matsuhisa M, Odawara M, Hirose T, Koshida R, Senda M, Tanaka Y, Terauchi Y. Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study). Expert Opin Pharmacother. 2020 Aug 25:1-8. doi: 10.1080/14656566.2020.1810665.
  9. Matsuba I, Kawata T, Iemitsu K, Asakura T, Amemiya H, Ishikawa M, Ito S, Kaneshiro M, Kanamori A, Kubota A, Shinoda K, Takai M, Takuma T, Takihata M, Takeda H, Tanaka K, Matsuzawa Y, Machimura H, Minagawa F, Minami N, Mokubo A, Miyakawa M, Terauchi Y, Tanaka Y. Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study. J Diabetes Investig. 2020 Mar 9;11(5):1248-57. doi: 10.1111/jdi.13248.
  10. Iwata W, Unoki-Kubota H, Kato H, Shimizu A, Matsumoto M, Imasawa T, Igarashi A, Matsumoto K, Noda T, Terauchi Y, Nangaku M, Kasuga M, Kaburagi Y. Podocyte-specific deletion of tubular sclerosis complex 2 promotes focal segmental glomerulosclerosis and progressive renal failure. PLoS One. 2020 Mar 19;15(3):e0229397.
  11. Nakaguchi H, Kondo Y, Kyohara M, Konishi H, Oiwa K, Terauchi Y. Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study. J Diabetes Investig. 2020 Apr 11. doi: 10.1111/jdi.13270.
  12. Terauchi Y, Nakama T, Spranger R, Amano A, Inoue T, Niemoeller E. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The LixiLan JP-O2 Randomized Clinical Trial. Diabetes Obes Metab. 2020 Apr 14. doi: 10.1111/dom.14036.
  13. Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Inverse correlation between serum high-molecular-weight adiponectin and proinsulin level in a Japanese population: The Dynamics of Lifestyle and Neighborhood Community on Health Study. J Diabetes Investig. 2020 Jun 12. doi: 10.1111/jdi.13323.
  14. Aoki K, Kamiyama H, Takihata M, Taguri M, Shibata E, Shinoda K, Yoshii T, Nakajima S, Terauchi Y. Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study. Endocr J. 2020 Sep 28;67(9):957-962.
  15. Odawara M, Matsuhisa M, Hirose T, Koshida R, Senda M, Tanaka Y, Terauchi Y. Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study). Expert Opin Pharmacother. 2020 Jul 22:1-10. doi: 10.1080/14656566.2020.1785430.
  16. Yamamoto S, Hachiya Y, Yuasa E, Takeuchi A, Ishidao T, Mihara M, Terauchi Y, Ichiba M, Hori H. Evaluation of the ceiling levels of ortho-phthalaldehyde exposure among health care workers engaged in endoscope disinfection: A new methodology using video-exposure monitoring. J Occup Health. 2020 Jan;62(1):e12139.
  17. Wang H, Mizuno K, Takahashi N, Kobayashi E, Shirakawa J, Terauchi Y, Kasai H, Okunishi K, Izumi T. Melanophilin Accelerates Insulin Granule Fusion Without Predocking to the Plasma Membrane. Diabetes. 2020 Sep 29:db200069. doi: 10.2337/db20-0069.
  18. Kyohara M, Shirakawa J, Okuyama T, Togashi Y, Inoue R, Li J, Miyashita D, Terauchi Y. Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects. Diabetol Metab Syndr. 2020 Sep 29;12:83. doi: 10.1186/s13098-020-00591-7.

2019年

  1. Yamakawa T, Sakamoto R, Takahashi K, Suzuki J, Matuura-Shinoda M, Takahashi M, Shigematsu E, Tanaka S, Kaneshiro M, Asakura T, Kawata T, Yamada Y, Osada UN, Isozaki T, Takahashi A, Kadonosono K, Terauchi Y. Dietary survey in Japanese patients with type 2 diabetes and the influence of dietary carbohydrate on glycated hemoglobin: The Sleep and Food Registry in Kanagawa study. J Diabetes Investig. 2018 Aug 1. doi: 10.1111/jdi.12903. [Epub ahead of print] PubMed PMID: 30070047.
  2. Yamamoto M, Terauchi Y, Sakuda A, Takahashi M. Binder-free sheet-type all-solid-state batteries with enhanced rate capabilities and high energy densities. Sci Rep. 2018 Jan 19;8(1):1212.
  3.  Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators. Achieving LDL cholesterol target levels <1.81 mmol/L may provide
    extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with
    Hypercholesterolaemia and Diabetic Retinopathy study. Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13575. [Epub ahead of print] PubMed PMID: 30393955.
  4.  Terauchi Y, Ozaki A, Zhao X, Teoh C, Jaffe D, Tajima Y, Shuto Y. Humanistic and economic burden of cardiovascular disease related comorbidities and hypoglycaemia among patients with type 2 diabetes in Japan. Diabetes Res Clin Pract. 2019 Jan 24. pii: S0168-8227(18)31334-2. doi: 10.1016/j.diabres.2019.01.019. [Epub ahead of print] PubMed PMID: 30685348.
  5.  Koike Y, Shirabe SI, Maeda H, Yoshimoto A, Arai K, Kumakura A, Hirao K, Terauchi Y. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019 Feb 1. pii: S0168-8227(18)31513-4. doi: 10.1016/j.diabres.2019.01.029. [Epub ahead of print] PubMed PMID: 30716347.
  6. Shinoda M, Yamakawa T, Takahashi K, Nagakura J, Suzuki J, Sakamoto R, Kadonosono K, Terauchi Y. PREVALENCE OF OBSTRUCTIVE SLEEP APNEA DETERMINED BY THE WATCHPAT IN NONOBESE JAPANESE PATIENTS WITH POOR GLUCOSE CONTROL AND TYPE 2 DIABETES. Endocr Pract. 2019 Feb;25(2):170-177. doi: 10.4158/EP-2018-0200. PubMed
    PMID: 30817196.
  7. Terauchi Y, Utsunomiya K, Yasui A, Seki T, Cheng G, Shiki K, Lee J. Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study. Diabetes Ther. 2019 Jun;10(3):951-963. doi: 10.1007/s13300-019-0604-8. Epub 2019 Mar 25. PubMed PMID: 30912033; PubMed Central PMCID: PMC6531579.
  8. Konishi H, Shirakawa J, Arai M, Terauchi Y. Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of evelolimus use with diabetes. Endocr J. 2019 Jun 28;66(6):571-574. doi: 10.1507/endocrj.EJ18-0553. Epub 2019 Apr 2. PubMed PMID: 30944270.
  9. Aoki K, Sato H, Terauchi Y. Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones. Endocr J. 2019 May 28;66(5):395-401. doi: 10.1507/endocrj.EJ19-0041. Epub 2019 Apr 23. PubMed PMID: 31019154.
  10. Takai M, Ishikawa M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A,
    Motomiya T, Waseda M, Miyakawa M, Terauchi Y, Tanaka Y, Matsuba I. Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study. J Clin Med Res. 2019 May;11(5):311-320. doi: 10.14740/jocmr3677. Epub 2019 Apr 14. PubMed PMID:
    31019624; PubMed Central PMCID: PMC6469892.
  11. Terauchi Y, Fujiwara H, Kurihara Y, Suganami H, Tamura M, Senda M, Gunji R, Kaku K. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. J Diabetes Investig. 2019 Nov;10(6):1518-1526. doi: 10.1111/jdi.13066. Epub 2019 May 28. PubMed PMID: 31033218; PubMed Central PMCID: PMC6825952.
  12. Goto A, Takao T, Yoshida Y, Kawazu S, Iwamoto Y, Terauchi Y. Causes of death and estimated life expectancy among people with diabetes: A retrospective cohort study in a diabetes clinic. J Diabetes Investig. 2019 May 21. doi: 10.1111/jdi.13077. [Epub ahead of print] PubMed PMID: 31111637.
  13. Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK, Christiansen E, Hertz CL, Haluzík M; PIONEER 1 Investigators. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019 Sep;42(9):1724-1732. doi: 10.2337/dc19-0749. Epub 2019 Jun 11. PubMed PMID: 31186300.
  14. Omori K, Nakamura A, Miyoshi H, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Takagi R, Hatanaka KC, Terauchi Y, Atsumi T. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. Metabolism. 2019 Sep;98:27-36. doi: 10.1016/j.metabol.2019.06.006. Epub 2019 Jun 14. PubMed PMID: 31202833.
  15. Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Proinsulin is sensitive to reflect glucose intolerance. J Diabetes Investig. 2019 Jun 21. doi: 10.1111/jdi.13106. [Epub ahead of print] PubMed PMID: 31222973.
  16. Suzuki J, Yamakawa T, Oba M, Nagakura J, Shigematsu E, Tamura H, Takahashi K, Okamoto Y, Sakamoto R, Shinoda M, Takano T, Kadonosono K, Terauchi Y. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an
    open-label, randomized controlled study. Endocr J. 2019 Nov 28;66(11):971-982. doi: 10.1507/endocrj.EJ18-0309. Epub 2019 Jul 4. PubMed PMID: 31270291.
  17. Miyazaki T, Shirakawa J, Nagakura J, Shibuya M, Kyohara M, Okuyama T, Togashi Y, Nakamura A, Kondo Y, Satoh S, Nakajima S, Taguri M, Terauchi Y. Influence of Timing of Insulin Initiation on Long-term Glycemic Control in Japanese Patients with Type 2 Diabetes: A Retrospective Cohort Study. Intern Med. 2019 Dec
    1;58(23):3361-3367. doi: 10.2169/internalmedicine.3060-19. Epub 2019 Jul 22. PubMed PMID: 31327835.
  18. Takihata M, Terauchi Y. The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study. Expert Opin Pharmacother. 2019 Dec;20(17):2185-2194. doi: 10.1080/14656566.2019.1656717. Epub 2019 Aug 26. PubMed PMID: 31450983.
  19. Kinguchi S, Wakui H, Ito Y, Kondo Y, Azushima K, Osada U, Yamakawa T, Iwamoto T, Yutoh J, Misumi T, Aoki K, Yasuda G, Yoshii T, Yamada T, Ono S, Shibasaki-Kurita T, Hosokawa S, Orime K, Hanaoka M, Sasaki H, Inazumi K, Yamada T, Kobayashi R, Ohki K, Haruhara K, Kobayashi Y, Yamanaka T, Terauchi Y, Tamura
    K. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Cardiovasc Diabetol. 2019 Aug 27;18(1):110. doi: 10.1186/s12933-019-0912-3. PubMed PMID: 31455298; PubMed Central PMCID: PMC6710883.

2018年

  1. Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). Diabetes Obes Metab. 2018 May;20(5):1176-1185.
  2. Yamamoto M, Terauchi Y, Sakuda A, Takahashi M. Binder-free sheet-type all-solid-state batteries with enhanced rate capabilities and high energy densities. Sci Rep. 2018 Jan 19;8(1):1212.
  3. Sakamoto R, Yamakawa T, Takahashi K, Suzuki J, Shinoda MM, Sakamaki K, Danno H, Tsuchiya H, Waseda M, Takano T, Minagawa F, Takai M, Masutani T, Nagakura J, Shigematsu E, Ishikawa M, Nakajima S, Kadonosono K, Terauchi Y. Association of usual sleep quality and glycemic control in type 2 diabetes in Japanese: A cross sectional study. Sleep and Food Registry in Kanagawa (SOREKA). PLoS One. 2018 Jan 24;13(1):e0191771.
  4. Kimura M, Kondo Y, Aoki K, Shirakawa J, Kamiyama H, Kamiko K, Nakajima S, Terauchi Y. A Randomized Controlled Trial of a Mini Low-Carbohydrate Diet and an Energy-Controlled Diet Among Japanese Patients With Type 2 Diabetes. J Clin Med Res. 2018 Mar;10(3):182-188.
  5. Ibuki A, Kuriyama S, Toyosaki Y, Aiba M, Hidaka M, Horie Y, Fujimoto C, Isami F, Shibata E, Terauchi Y, Akase T. Aging-like physiological changes in the skin of Japanese obese diabetic patients. SAGE Open Med. 2018 Feb 6;6:2050312118756662.
  6. Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Serum adiponectin and insulin secretion: A direct or inverse association? J Diabetes Investig. 2018 Feb 16. doi: 10.1111/jdi.12821. [Epub ahead of print] PubMed PMID: 29451743.
  7. Yamada Y, Terauchi Y, Watada H, Nakatsuka Y, Shiosakai K, Washio T, Taguchi T. Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study. Adv Ther. 2018 Mar;35(3):367-381.
  8. Inoue H, Shirakawa J, Togashi Y, Tajima K, Okuyama T, Kyohara M, Tanaka Y, Orime K, Saisho Y, Yamada T, Shibue K, Kulkarni RN, Terauchi Y. Signaling between pancreatic β cells and macrophages via S100 calcium-binding protein A8 exacerbates β-cell apoptosis and islet inflammation. J Biol Chem. 2018 Apr 20;293(16):5934-5946.
  9. Kitao N, Nakamura A, Miyoshi H, Nomoto H, Takahashi K, Omori K, Yamamoto K, Cho KY, Terauchi Y, Atsumi T. The role of glucokinase and insulin receptor substrate-2 in the proliferation of pancreatic beta cells induced by short-term high-fat diet feeding in mice. Metabolism. 2018 Mar 12. pii: S0026-0495(18)30082-9. doi: 10.1016/j.metabol.2018.03.010. [Epub ahead of print]
  10. Terauchi Y, Yamada Y, Watada H, Nakatsuka Y, Shiosakai K, Washio T, Taguchi T. Efficacy and safety of the G protein-coupled receptor 119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo-controlled study. J Diabetes Investig. 2018 Apr 1. doi: 10.1111/jdi.12846. [Epub ahead of print]
  11. Miya A, Nakamura A, Miyoshi H, Takano Y, Sunagoya K, Hayasaka K, Shimizu C, Terauchi Y, Atsumi T. Impact of Glucose Loading on Variations in CD4(+) and CD8(+) T Cells in Japanese Participants with or without Type 2 Diabetes. Front Endocrinol (Lausanne). 2018 Mar 20;9:81.
  12. Watada H, Shiramoto M, Irie S, Terauchi Y, Yamada Y, Shiosakai K, Myobatake Y, Taguchi T. G protein-coupled receptor 119 agonist DS-8500a effects on pancreatic β-cells in Japanese type 2 diabetes mellitus patients. J Diabetes Investig. 2018 Apr 6. doi: 10.1111/jdi.12849. [Epub ahead of print]
  13. Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care. 2018 Jun;41(6):1275-1284.
  14. Takahashi K, Nakamura A, Miyoshi H, Nomoto H, Kitao N, Omori K, Yamamoto K, Cho KY, Terauchi Y, Atsumi T. Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages. Sci Rep. 2018 May 1;8(1):6864.
  15. Terauchi Y, Riddle MC, Hirose T, Koyama M, Cheng X, Takahashi Y, Bolli GB. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: a 12-month comparison by concomitant sulphonylurea and/or glinide use. Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13414. [Epub ahead of print]
  16. Shirakawa J, Terauchi Y. SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. Ann Transl Med. 2018 Apr;6(7):129.
  17. Chiba Y, Yamakawa T, Tsuchiya H, Oba M, Suzuki D, Danno H, Takatsuka Y, Shigematsu H, Kaneshiro M, Terauchi Y. Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus. J Clin Med Res. 2018 Aug;10(8):648-656.
  18. Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database. Diabetes Care. 2018 Sep;41(9):e130-e132. 
  19.  Aoki K, Terauchi Y. Effect of Dehydroepiandrosterone (DHEA) on Diabetes Mellitus and Obesity. Vitam Horm. 2018;108:355-365.
  20. Osada UN, Terauchi Y. The new basal insulin analog glargine U-300 enables flexible injection schedule. Ann Transl Med. 2018 Nov;6(Suppl 1):S1.

2017年

  1. Takahashi K, Nakamura A, Miyoshi H, Nomoto H, Kameda H, Cho KY, Nagai S, Shimizu C, Taguri M, Terauchi Y, Atsumi T. Factors associated with an inadequate hypoglycemia in the insulin tolerance test in Japanese patients with suspected or proven hypopituitarism. Endocr J. 2017 64(4):387-392
  2. Seino Y, Terauchi Y, Wang X, Watanabe D, Niemoeller E; study investigators.. Safety, tolerability, and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.J Diabetes Investig. 2017 Feb 13. doi: 10.1111/jdi.12646. [Epub ahead of print]
  3. Terauchi Y, Yamada Y, Ishida H, Ohsugi M, Kitaoka M, Satoh J, Yabe D, Shihara N, Seino Y. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).  Diabetes Obes Metab. 2017 Aug;19(8):1188-1192.
  4. Miya A, Nakamura A, Miyoshi H, Cho KY, Nagai S, Kurihara Y, Aoki S, Taguri M, Terauchi Y, Atsumi T. Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: a randomized controlled trial.J Diabetes Investig. 2017 Mar 10. doi: 10.1111/jdi.12654. [Epub ahead of print]
  5. Terauchi Y, Koyama M, Cheng X, Sumi M, Riddle MC, Bolli GB, Hirose T, on behalf of the EDITION JP 2 study group. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral antihyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension)Diabetes Metabolism, in press, 2017.
  6. Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes Obes Metab. 2017 Mar 30. doi: 10.1111/dom.12957. [Epub ahead of print] PubMed PMID:
    28371205.
  7. Terauchi Y, Kim YK, Tanaka T, Nanatani K, Takahashi T, Abe K. Asp30 of Aspergillus oryzae cutinase CutL1 is involved in the ionic interaction with fungal hydrophobin RolA. Biosci Biotechnol Biochem. 2017 Jul;81(7):1363-1368.
  8. Tajima K, Shirakawa J, Okuyama T, Kyohara M, Yamazaki S, Togashi Y, Terauchi Y. Effects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2017 May 16:ajpendo.00447.2016. doi: 10.1152/ajpendo.00447.2016. [Epub ahead of print] PubMed PMID: 28512156.
  9. Okuyama T, Shirakawa J, Yanagisawa H, Kyohara M, Yamazaki S, Tajima K, Togashi Y, Terauchi Y. Identification of the matricellular protein Fibulin-5 as a target molecule of glucokinase-mediated calcineurin/NFAT signaling in pancreatic islets. Sci Rep. 2017 May 24;7(1):2364.
  10. Shigematsu E, Yamakawa T, Oba MS, Suzuki J, Nagakura J, Kadonosono K, Terauchi Y. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes. J Clin Med Res. 2017 Jul;9(7):567-572.
  11. Kawata T, Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus. J Clin Med Res. 2017 Jul;9(7):586-595.
  12. Tajima K, Shirakawa J, Togashi Y, Yamazaki S, Okuyama T, Kyohara M, Konishi H, Terauchi Y. Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906. Sci Rep. 2017 Jun 23;7(1):4119.
  13. Aoki K, Nagakura M, Taguri M, Kamiyama H, Masumura M, Furuie T, Oka M, Kamiko K, Nakajima S, Akema N, Terauchi Y. Effect of Switching From an Anti-Diabetic Loose Dose Combination to a Fixed Dose Combination Regimen at Equivalent Dosage for 6 Months on Glycemic Control in Japanese Patients With Type 2 Diabetes: A Pilot Study. J Clin Med Res. 2017 Aug;9(8):719-724.
  14. Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, Zacho J, Kaneko S. Safety and efficacy of semaglutide once weekly versus sitagliptin once daily, both as monotherapy in Japanese subjects with type 2 diabetes. Diabetes Obes Metab. 2017 Aug 8. doi: 10.1111/dom.13082. [Epub ahead of print] PubMed PMID: 28786547.
  15. Iemitsu K, Kawata T, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyanagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study. J Clin Med Res. 2017 Sep;9(9):793-801.
  16. Minami T, Yamada M, Furuta R, Kamata K, Katsuragawa S, Terui S, Akiyama T, Yoshii T, Tsunoda T, Terauchi Y. Predicting the ability of elderly diabetic patients to acquire the insulin self-injection technique based on the number of animal names recalled. J Diabetes Investig. 2017 Aug 28. doi: 10.1111/jdi.12732. [Epub ahead of print] PubMed PMID: 28846204.
  17. Gonai M, Shigehisa A, Kigawa I, Kurasaki K, Chonan O, Matsuki T, Yoshida Y, Aida M, Hamano K, Terauchi Y. Galacto-oligosaccharides ameliorate dysbiotic Bifidobacteriaceae decline in Japanese patients with type 2 diabetes. Benef Microbes. 2017 Sep 8:1-12. doi: 10.3920/BM2016.0230. [Epub ahead of print] PubMed PMID: 28884590.
  18. Amagai M, Tsuchiya H, Chiba Y, Suzuki J, Nagakura J, Shigematsu E, Yamakawa T, Terauchi Y. Incretin Kinetics Before and After Miglitol in Japanese Patients With Late Dumping Syndrome. J Clin Med Res. 2017 Oct;9(10):879-885.
  19. Kyohara M, Shirakawa J, Okuyama T, Kimura A, Togashi Y, Tajima K, Hirano H, Terauchi Y. Serum Quantitative Proteomic Analysis Reveals Soluble EGFR To Be a Marker of Insulin Resistance in Male Mice and Humans. Endocrinology. 2017 Dec 1;158(12):4152-4164.
  20. Yamada E, Namiki Y, Takano Y, Takamine H, Inazumi K, Sasaki H, Yamada M, Ito S, Iwasaki T, Mantani N, Minami T, Osada UN, Terauchi Y, Nakajima A. Clinical factors associated with the symptoms of constipation in patients with diabetes mellitus: a multicenter study. J Gastroenterol Hepatol. 2017 Oct 19. doi: 10.1111/jgh.14022. [Epub ahead of print]
  21.  Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964.

 2016年

  1. Orime K, Shirakawa J, Togashi Y, Tajima K, Inoue H, Nagashima Y, Terauchi Y. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model. Eur J Pharmacol, 772: 22-32, 2016.
  2. Nagakura J, Yamakawa T, Taguri M, Tsuchiya H, Shigematsu E, Suzuki J, Morita S, Kadonosono K, Terauchi Y. Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes. Endocr J. 63(3): 239-47, 2016.
  3. Kamiyama H, Aoki K, Nakajima S, Shinoda K, Kamiko K, Taguri M, Terauchi Y. Effect of switching from sulphonylurea to repaglinide twice or three times daily for 4 months on glycemic control in Japanese patients with type 2 diabetes. Intern Med, in press, 2016.
  4. Terauchi Y, Yokote K, Nakamura I, Sugamori H. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study. Expert Opin Pharmacother. 17(4): 463-71, 2016.
  5. Goto A, Goto M, Terauchi Y, Yamaguchi N, Noda M. Association between severe hypoglycemia and cardiovascular disease risk in Japanese patients with type 2 diabetes. JAHA, 2016 Mar 9;5(3). pii: e002875.
  6. Shirakawa J, Okuyama T, Kyohara M, Yoshida E, Togashi Y, Tajima K, Yamazaki S, Kaji M, Koganei M, Sasaki H, Terauchi Y. DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid. Diabetes Metab Syndr. 2016 Mar 1;8:16.
  7. Shibata E, Aoki K, Tajima K, Taguri M, Terauchi Y. Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes. Expert Opin Pharmacother. 17(7): 889-94, 2016.
  8. Watanabe Y, Eto T, Taniguchi S, Terauchi Y. Risk of diabetes after 5 years among those with high-normal fasting plasma glucose Intern Med, in press, 2016.
  9. Aoki K, Tajima K, Taguri M, Terauchi Y. Effect of dehydroepiandrosterone (DHEA) on Akt and protein kinase C zeta (PKCζ) phosphorylation in different tissues of C57BL6, insulin receptor substrate (IRS)1-/-, and IRS2-/- male mice fed a high-fat diet. J Steroid Biochem Mol Biol. 2016 May;159:110-20.
  10. Iemitsu K, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Obana M, Sasai N, Kaneshige H, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study. J Clin Med Res. 2016 May; 8(5): 373-8.
  11. Togashi Y, Shirakawa J, Okuyama T, Kyohara M, Yamazaki S, Miyazawa A, Suzuki T, Hamada M, Terauchi Y. Evaluation of blood glucose meters for measuring mouse blood glucose levels. Scientific Reports, 2016 May 6;6:25465.
  12. Nezu Osada U, Sunagawa H, Asato T, Terauchi Y, Ueda S. A Common Susceptible Gene for Type 2 Diabetes is associated with Drug Response to DPP-4 inhibitor: Pharmacogenomic Cohort in Okinawa Japan. PLoS One. 2016 May 3;11(5):e0154821.
  13. Yuasa S, Sato K, Takai M, Ishikawa M, Umezawa S, Kubota A, Maeda H, Kanamori A, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes. J Clin Med Res. 2016 Jun;8(6):461-71.
  14. Noto H, Tanizawa Y, Aizawa T, Sone H, Yoshioka N, Terauchi Y, Inagaki N, Noda M. Cluster-randomized trial to improve the quality of diabetes management: The study for the efficacy assessment of the standard diabetes manual (SEAS-DM). J Diabetes Investig. 2015 Dec 12. doi: 10.1111/jdi.12455. [Epub ahead of print]
  15. Suzuki J, Yamakawa T, Nagakura J, Shigematsu E, Kadonososno K, Terauchi Y. Efficacy of switching from insulin glargine to insulin degludec in patients with type 1 diabetes: a 16-week retrospective study. Diabetology International . 2016 doi: 10.1007/s13340-016-0275-x [Epub ahead of print]
  16.  16.  Nakamura A, Iwami D, Miyoshi H, Morita K, Taguri M, Terauchi Y, Shinohara N, Atsumi T. Impact of renal transplantation on glucose tolerance in Japanese recipients with impaired glucose tolerance.Diabetic Med. 2016 Aug 9. doi:         0.1111/dme.13199.          [Epub      ahead of print]
  17. Yokote K, Terauchi Y, Nakamura I, Sugamori H. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Final results of a post-marketing surveillance study.     Dpert Opin       Pharmacother. 17(15): 1995-2003, 2016.
  18. Shirakawa J, Terauchi Y. Glucose- or insulin resistance-mediated β-cell replication: PKCζ integrates the proliferative signaling.J Diabetes Investig. 2016 Aug 1. doi: 10.1111/jdi.12558. [Epub ahead of print]
  19. Kubota N, Kubota T, Kajiwara E, Iwamura T, Kumagai H, Watanabe T, Inoue M, Takamoto I, Sasako T, Kumagai K, Kohjima M, Nakamuta M, Moroi M, Sugi K, Noda T, Terauchi Y, Ueki K, Kadowaki T. Differential hepatic distribution of insulin receptor    substrates causes selective insulin resistance in diabetes and obesity.Nature Communications 2016 Oct 6;7:12977. doi: 10.1038/ncomms12977.
  20. Kamiko K, Aoki K, Kamiyama H, Taguri M, Terauchi Y. Comparison of plasma glucose and gut hormone levels between drinking enteral formula over a period of 5 and 20 minutes in Japanese patients with type 2 diabetes: A pilot study.J Clin Med Res. 2016   Oct;8(10):749-52.
  21. Kubota T, Kubota N, Sato H, Inoue M, Kumagai H, Iwamura T, Takamoto I, Kobayashi T, Moroi M, Terauchi Y, Tobe K, Ueki K, Kadowaki T. Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways.Scientific Reports 2016 Oct 5;6:34707. doi: 10.1038/srep34707.
  22. Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, Iida M, Sano H, Tomiyama H, Inoue T, Tanaka A, Murohara T, Node K; PROLOGUE Study Investigators. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.Cardiovasc Diabetol2016 Sep 13;15(1):134.
  23. Tsunoda T, Yamada M, Akiyama T, Minami T, Yoshii T, Kondo Y, Satoh S, Terauchi Y. The Effects of Ramelteon on Glucose Metabolism and Sleep Quality in Type 2 Diabetic Patients With Insomnia: A Pilot Prospective Randomized Controlled Trial.J Clin    Med  Res. 2016 Dec;8(12):878-887.

2015年

  1. Kamiko K, Aoki K, Kamiyama H, Taguri M, Shibata E, Ashiya Y, Minagawa F, Shinoda K, Nakajima S, Terauchi Y. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: A randomized non-inferior test.J Clin Pharmacol. 55(2): 144-151, 2015.
  2. Nakamura A, Terauchi Y. Present status of clinical deployment of glucokinase activators. [Review]J Diabetes Invest, 6: 124-132, 2015.
  3. Inoue Y, Nakamura A, Kondo Y, Hamano K, Satoh S, Terauchi Y. A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.J Clin Pharmacol, 55(7): 831-8, 2015.
  4. Nozaki Y, Fujita K, Wada K, Yoneda M, Kessoku T, Shinohara Y, Imajo K, Ogawa Y, Nakamuta M, Saito S, Masaki N, Nagashima Y, Terauchi Y, Nakajima A. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.BMC Gastroenterology, 15(1): 42, 2015.
  5. Maeda H, Kubota A, Kanamori A, Tanaka Y, Terauchi Y, Matsuba I, The Study Group of the Diabetes Committee, Kanagawa Physicians Association. Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes.Diabetes Res. Clin. Pract., 108(3):e42-5, 2015.
  6. Ishikawa M, Takai M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Tsurui N, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A, Motomiya T, Waseda M, Miyakawa M, Naka Y, Terauchi Y, Tanaka Y, Matsuba I. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and insulin in type 2 diabetic patients: The ASSIST-K Study.J Clin Med Res, 7(8):607-12, 2015.
  7. Takihata M, Nakamura A, Kondo Y, Kawasaki S, Kimura M, Terauchi Y. Comparison of azelnidipine and trichlormethiazide in Japanese type 2 diabetic patients with hypertension: the COAT randomized controlled trial.PloS ONE, 2015 May 4;10(5):e0125519.
  8. Inoue K, Goto A, Kishimoto M, Tsujimoto T, Yamamoto-Honda R, Noto H, Kajio H, Terauchi Y, Noda M. Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases.Clin Exp Nephrol. 2015 Apr 1. [Epub ahead of print]
  9. Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, Rattunde H, Woerle HJ, Broedl UC. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: A randomized, double-blind, parallel-group study.Adv Ther. 32(4):306-18, 2015.
  10. Aoki K, Iijima T, Kamiyama H, Kamiko K, Terauchi Y. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: A pilot study.Expert Opin Pharmacother, 2015 Jun 22:1-6. [Epub ahead of print]
  11. Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, Okuyama K, Juan Camilo Arjona Ferreira, Goldstein BJ. Sitagliptin improves glycemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance.Diabetes Obes Metab, 2015 Jun 12. doi: 10.1111/dom.12507. [Epub ahead of print]
  12. Umezawa  S, Kubota  A, Maeda  H, Kanamori  A, Matoba  K, Jin  Y, Minagawa  F, Obana  M, Iemitsu  K, Ito  S, Amamiya  H, Kaneshiro  M, Takai  M, Kaneshige  H, Hoshino  K, Ishikawa  M, Minami  N, Takuma  T, Sasai  N, Aoyagi  S, Kawata  T, Mokubo  A, Miyairi  Y, Takeda  H, Honda  S, Machimura  H, Motomiya  T, Waseda  M, Naka  Y, Tanaka  Y, Terauchi  Y, Matsuba  I. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.BMC Endocrine Disorders, 2015 Jul 3;15:34.
  13. Kondo Y, Satoh S, Nezu Osada U, Terauchi Y. Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: A retrospective cohort study.Endocr J, in press, 2015.
  14. Yoshii T, Yamada M, Minami T, Tsunoda T, Sasaki M, Kondo Y, Satoh S, Terauchi Y. The effects of bazedoxifene on bone, glucose, and lipid metabolism in postmenopausal women with type 2 diabetes: An exploratory pilot study.J Clin Med Res, in press, 2015.
  15. Ono K, Nakamura A, Kawaguchi J, Takihata M, Inoue Y, Shirakawa J, Kameda A, Togashi Y, Hayashi T, Furuki T, Ito S, Takano T, Kawasaki S, Takeda H, Kaneko T, Kimura M, Mizushima S, Terauchi Y. The Safety, Efficacy and Treatment Satisfaction Comparison of Unchanged Premixed Insulin Regimen Plus Sitagliptin with Switch from the Premixed Insulin to Once-Daily Basal Insulin Plus Sitagliptin in Patients with Inadequately Controlled Type 2 Diabetes with Twice-Daily Premixed Insulin.Int J Diabetes Clin Res 2:4, 2015.
  16. Terauchi Y, Naito Y, Ikeda Y. Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients.Diabetes Metab Syndr. 2015 Aug 22. pii: S1871-4021(15)00075-2.
  17. Emoto M, Terauchi Y, Ozeki A, Oura T, Takeuchi M, Imaoka T. A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.Endocr. J., in press, 2015.
  18. Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Efficacy and Safety of Ipragliflozin in Japanese Patients with Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.J Clin Med Res, in press, 2015.
  19. Nakamura A, Mitsuhashi T, Takano Y, Miyoshi H, Kameda H, Nomoto H, Nagai S, Hatanaka Y, Shimizu C, Terauchi Y, Atsumi T. Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas.Endocr J. 2015 Nov 14. [Epub ahead of print]
  20. Komatsu Y, Nakamura A, Takihata M, Inoue Y, Yahagi S, Tajima K, Tsuchiya H, Takano T, Yamakawa T, Yoshida M, Miyoshi H, Terauchi Y. Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia.Endocr J. 2015 Nov 20. [Epub ahead of print]
  21. Ito Y, Shibuya M, Hosokawa S, Motoki Y, Nagata R, Konishi H, Miyazaki T, Matsunaga T, Nomura Y, Mihara T, Ito S, Sugiura K, Terauchi Y. Indicators of the need for insulin treatment and the effect of treatment for gestational diabetes on pregnancy outcomes in Japan.Endocr J. 2015 Nov 25. [Epub ahead of print]
  22. Terauchi Y, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, Hirose T. New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drug(s): glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).Diabetes Obes Metab, 2015 Dec 11. doi: 10.1111/dom.12618. [Epub ahead of print]
  23. Okamoto Y, Yamakawa T, Terauchi Y. Aging may affect insulin action independent of adiposity in non-diabetic subjects. [Review]J Atheroscler Thromb. 2015 Dec 19. [Epub ahead of print]
  24. Nozaki Y, Fujita K, Wada K, Yoneda M, Shinohara Y, Imajo K, Ogawa Y, Kessoku T, Nakamuta M, Saito S, Masaki N, Nagashima Y, Terauchi Y, Nakajima A. Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution BMC Gastroenterol. 2015 Dec 17;15(1):177.

2014年

  1. Kondo Y, Hamai J, Nezu U, Shigematsu E, Kamiko K, Yamazaki S, Takahashi M, Takano T, Kawasaki S, Yamada M, Yamakawa T, Terauchi Y. Second-line    treatments   in   dyslipidemic patients at risk of cardiovascular disease.Endocr J, 61(4): 343-51, 2014.
  2. Togashi Y, Shirakawa J, Orime K, Kaji M, Sakamoto E, Tajima K, Inoue H, Nakamura A, Tochino Y, Goshima Y, Shimomura I, Terauchi Y. β cell proliferation after a partial pancreatectomy is independent of IRS-2 in mice.Endocrinology, 155(5), 1643-52.2014.
  3. Shirakawa J, Terauchi Y. Selective and sequential loss of transcriptional factors: a hallmark of β cell failure in type 2 diabetes? Diabetes Invest, 5(4):359-61, 2014. [Review]
  4. Yamakawa T, Ogihara K, Utsunomiya H, Muraoka T, Kadonosono K, Terauchi Y. Colestimide improve glycemic control via hepatic glucose production in db/db mice.Endocr J, 61(5): 425-36, 2014.
  5. Takai M, Ishikawa M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Tsurui N, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A, Motomiya T, Waseda M, Miyakawa M, Naka Y, Terauchi Y, Tanaka Y, Matsuba I. Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: The ASSIST-K study.Diabetes Res Clin Pract. 103(3): e30-3, 2014.
  6. Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K, Iwamoto Y, Watada H, Ohtsuka W, Watanabe D, Suganami H; for the Tofogliflozin 004 and 005 Study group. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.Expert Opin Pharmacother. 15(6):749-66, 2014.
  7. Kawata T, Kanamori A, Kubota A, Maeda H, Amamiya H, Takai M, Kaneshige H, Minagawa F, Iemitsu K, Kaneshiro M, Ishikawa M, Takeda H, Takuma T, Mokubo A, Machimura H, Obana M, Miyakawa M, Naka Y, Suzuki D, Terauchi Y, Toyoda M, Tanaka Y, Matsuba I. Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients?J Clin Med Res. 6(2):138-44, 2014.
  8. Shirakawa J, Okuyama T, Yoshida E, Shimizu M, Horigome Y, Tuno T, Hayasaka M, Abe S, Fuse M, Togashi Y, Terauchi Y. Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, β cell functions, and β cell proliferation in male miceEndocrinology, 155(6): 2102-11, 2014.
  9. Inoue K, Tsujimoto T, Yamamoto-Honda R, Goto A, Kishimoto M, Noto H, Kajio H, Doi S, Miyazaki S, Terauchi Y, Noda M. A newer conversion equation for the correlation between HbA1c and glycated albumin.Endocr J. 61(6): 553-60, 2014.
  10. Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.Cardiovasc Diabetol. 28;13(1): 65, 2014.
  11. Kamiyama H, Aoki K, Nakajima S, Shinoda K, Kamiko K, Taguri M, Terauchi Y. Effect of repaglinide therapy administered twice or thrice daily for 3 months on glycemic control in Japanese patients with type 2 diabetes.J Int Med Res42(5):1150-60, 2014.
  12. Terauchi Y, Satoi Y, Takeuchi M, Imaoka T. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.Endocr. J. 61(10):949-59, 2014.
  13. Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, Rattunde H, Woerle HJ, Broedl UC. Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial.Adv Ther31(6): 621-38, 2014.
  14. Miyazaki Y, Yusa T, Matsuo S, Terauchi Y, Miyazaki S. Zyxin modulates the transmigration of Haemophilus influenzae to the central nervous system.Virulence. 5(6): 665-72, 2014.
  15. Shirakawa J, Murohashi Y, Okazaki N, Yamazaki S, Tamura T, Okuyama T, Togashi Y, Terauchi Y. Using miglitol at 30 min before meal is effective in hyperinsulinemic hypoglycemia after a total gastrectomy.Endocr. J. 61(11): 1115-23, 2014.
  16. Sato K, Satoh S, Muraoka T, Miyazaki Y, Kikuchi K, Terauchi Y. Evidence of brain atrophy detected on magnetic resonance imaging is associated with failure of acquisition of the ability for insulin self-injection. Endocr. J. 61(11): 1125-30, 2014.
  17. Shigematsu E, Yamakawa T, Kadonosono K, Terauchi Y. Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus. J Clin Med Res. 6(5): 327-35, 2014.
  18. Kamiko K, Aoki K, Kamiyama H, Taguri M, Shibata E, Ashiya Y, Minagawa F, Shinoda K, Nakajima S, Terauchi Y. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: A randomized non-inferior test.J Clin Pharmacol. 2014 Aug 27. doi: 10.1002/jcph.385. [Epub ahead of print]
  19. Nakamura A, Yoneda M, Sumida Y, Miyoshi H, Nakajima A, Atsumi T, Terauchi Y. A caution in the use of the NAFIC scoring system as a diagnostic screening tool for nonalcoholic steatohepatitis.Gastrointestinal Digestive System. in press, 2014.
  20. Nakamura A, Terauchi Y. Present status of clinical deployment of glucokinase activators.J Diabetes Investig. in press, 2014. [Review]

2013年

  1. Takihata M, Nakamura A, Tajima K Komatsu Y, Tamura H, Yamazaki S, Kondo Y, Yamada M, Kimura M, Terauchi Y. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.Diabetes Obes. Metab., 15(5): 455-62, 2013.
  2. Maeda H, Kubota A, Kanamori A, Tanaka Y, Terauchi Y, Matsuba I. ASSET-K Study Group. Long-term efficacy and safety of sitagliptin in the treatment of Japanese type 2 diabetes (ASSET-K1) to a target of HbA1c <7%. J Endocrinol Invest, 36(8): 568-73, 2013.
  3. Ishii H, Terauchi Y, Jinnouchi H, Taketsuna M, Tsuji I, Takeuchi M. Effects of insulin changes on quality of life and glycaemic control in Japanese patients with type 2 diabetes mellitus: the INSIGHTs observational study. J Diabetes Invest, in press, 2013.
  4. Masuda K, Aoki K, Kamiko K, Takihata M, Ito Y, Nagakura M, Kawasaki S, Akema N, Hasegawa M, Nakajima S, Toumura S, Tsunoda S, Enomoto H, Shimotomai H, Terauchi Y. Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a day treatment with a-glucosidase inhibitors. Expert Opinion on Pharmacotherapy, 14(9):1111-8, 2013.
  5. Goto A, Morita A, Goto M, Sasaki S, Miyachi M, Aiba N, Kato M, Terauchi Y, Noda M, Watanabe S; for the Saku cohort Study Group. Validity of diabetes self-reports in the Saku Diabetes Study. J Epidemiology, 23(4):295-300, 2013.
  6. Kondo Y, Satoh S, Nagakura J, Kimura M, Nezu U, Terauchi Y. Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetesJ Diabetes Invest, in press, 2013.
  7. Nakamura A, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Okanoue T, Nakajima A, Maeda S, Terauchi Y. Modification of a simple clinical scoring system as a diagnostic screening tool for nonalcoholic steatohepatitis in Japanese patients with nonalcoholic fatty liver disease.J Diabetes Invest, in press, 2013.
  8. Tajima K, Shirakawa J, Togashi Y, Inoue H, Sato K, Orime K, Ito Y, Kaji M, Sakamoto E, Nakamura A, Aoki K, Goshima Y, Atsumi T, Terauchi Y. AMPK is involved in the regulation of incretin receptors expression in pancreatic islets under a low glucose concentration.PLoS One. 2013 May 22;8(5):e64633. doi: 10.1371/journal.pone.0064633.
  9. Masuda K, Kawaguchi J, Aoki K, Yamakawa T, Matsuba I, Terauchi Y. Effect of instruction on caloric intake (25 or 30 kcal/ kg [ideal body weight]/ day) on the degree of glycemic control and improvement of lipid profile in obese patients with type 2 diabetes: a prospective, randomized, controlled, multicenter study (25 or 30 study).J Clin Med Res, 5(5): 368-75, 2013.
  10. Shirakawa J, Togashi Y, Sakamoto E, Kaji M, Tajima K, Orime K, Inoue H, Kubota N, Kadowaki T, Terauchi Y. Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic β cells.Diabetes, 62(10): 3448-58, 2013.
  11. Goto M, Goto A, Morita A, Deura K, Sasaki S, Aiba N, Shimbo T, Terauchi Y, Miyachi M, Noda M, Watanabe S; Saku Cohort Study Group. Low-molecular-weight adiponectin and high-molecular-weight adiponectin levels in relation to diabetes.Obesity (Silver Spring). 2013 Jul 1. doi: 10.1002/oby.20553. [Epub ahead of print]
  12. Goto A, Arah OA, Goto M, Terauchi Y, Noda M, Severe Hypoglycaemia and Cardiovascular Disease: A Systematic Review and Meta-Analysis with Bias Analysis.BMJ, Jul 29;347:f4533. doi: 10.1136/bmj.f4533.
  13. Zolzaya K, Nakamura A, Tajima K, Terauchi Y. Role of insulin receptor substrate-1 for diethylnitrosamine plus high-fat diet-induced hepatic tumorigenesis in mice.J Diabetes Invest, in press, 2013
  14. Takihata M, Nakamura A, Aoki K, Kimura M, Sekino Y, Inamori M, Maeda S, Gotoh E, Nakajima A, Terauchi Y. Comparison of intragastric balloon therapy and intensive lifestyle modification therapy with respect to weight reduction and abdominal fat distribution in super-obese Japanese patients.Obes Res Clin Pract, in press, 2013.
  15. Tajima K, Nakamura A, Shirakawa J, Togashi Y, Orime K, Sato K, Inoue H, Kaji M, Sakamoto E, Ito Y, Aoki K, Nagashima Y, Atsumi T, Terauchi Y. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 Mice.Am. J. Physiol. Endocrinol. Metab., 305(8): E987-98, 2013.
  16. Kawata T, Kanamor A, Kubota A, Maeda H, Matoba K, Jin Y, Ito S, Amamiya H, Takai M, Kaneshige H, Minami N, Minagawa F, Iemitsu K, Kaneshiro M, Hoshino K, Ishikawa M, Takeda H, Motomiya T, Takuma T, Aoyagi S, Mokubo A, Machimura H, Obana M, Miyakawa M, Naka Y, Terauchi Y, Toyoda M, Suzuki D, Tanaka Y, Matsuba I. Clinical Effects of Liraglutide on Diabetes Control in Japanese Type 2 Diabetes Mellitus Patients. Diabetology International, in press
  17. Orime K, Shirakawa J, Togashi Y, Tajima K, Inoue H, Ito Y, Sato K, Nakamura A, Aoki K, Goshima Y, Terauchi Y. Trefoil factor 2 promotes cell proliferation in pancreatic β cells through CXCR-4-mediated ERK1/2 phosphorylation.Endocrinology, 154(1): 54-64, 2013.
  18.  Nakamura A, Terauchi Y. Lessons from mouse models of high-fat diet-induced NAFLD.Int J Med Sci, 14(11):21240-57, 2013.
  19. Kawasaki S, Misawa H, Tamura Y, Kondo Y, Satoh S, Hasegawa O, Kato S, Terauchi Y. Relationship between Coronary Artery Disease and Retinopathy in Patients with Type 2 Diabetes Mellitus.Intern Med, 52(22): 2483-7, 2013.
  20. Ono K, Yamasue K, Tochikubo O, Terauchi Y, Mizushima S. Lifestyle modification system with use of earphone-type thermometer, ABPM and wrist-type pulse rate recorder.Clin Exp Hypertens, in press, 2013.
  21. Aoki K, Kamiyama H, Masuda K, Kamiko K, Noguchi Y, Tajima K, Terauchi Y. Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels.Endocr J, in press, 2013.
  22. Nakamura A, Hagiwara E, Hamai J, Taguri M, Terauchi Y. Impact of underlying diabetes and the presence of cavity on the treatment outcomes in patients with pulmonary tuberculosis.Diabetic Medicine, in press, 2013.
  23. Kato S, Fukui K, Kawaguchi J, Ishii N, Koga M, Kusakawa Y, Kusama I, Nakachi T, Nakagawa T, Terauchi Y, Uchino K, Kimura K, Umemura S. Relationship between coronary flow reserve evaluated by phase-contrast cine cardiovascular magnetic resonance and serum eicosapentaenoic acid.J Cardiovasc Magn Reson. 2013 Dec 20;15(1):106.